iNova Pharmaceuticals Pty. Ltd.

The summer of 2020 has been a busy one for US biopharmaceutical company initial public offerings, but after 14 in June and 12 in July there were just six in August – although that’s still the third mo

Former Merck & Co. Inc. China R&D head Zhengqing Li , who left the position to become chief medical officer and head of Greater China R&D for Chinese venture Ascletis Pharma Inc. , has returned to

Valeant Pharmaceuticals International Inc. has made important debt-reduction progress, meeting its goal ahead of schedule, but the company's near-term growth story remains lackluster. The company tol

Just over two years after buying Sprout Pharmaceuticals Inc. and its controversial female sexual dysfunction drug Addyi (flibanserin) for $1bn, Valeant Pharmaceuticals International Inc. has